Biodexa Hits Major Milestone in Serenta Phase 3 FAP Trial
BDRX sits 42% above its 52-week low of $1.02 on light trading volume (0.1× avg).
Summary
Biodexa announced a major milestone for its Serenta registrational Phase 3 trial in familial adenomatous polyposis (FAP). The company has not disclosed the specific nature of the milestone, but the term 'major' suggests a significant advancement, such as completion of enrollment, a positive interim analysis, or a regulatory interaction. This follows a period of heavy dilution and a 1-for-10,000 reverse split approved in July, making any positive clinical progress critical for the company's outlook. The milestone could de-risk the program and support the stock's recent stabilization. Investors will look for details on the milestone and upcoming data readouts.
At the time of this announcement, BDRX was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $1.02 to $59.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.